The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp. or Coccidia sp based diseases or other enteric diseases or by generally improving gastro intestinal health or function

Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.

This document provides methods and materials involved in assessing mammals (e.g., humans) for arthritis. For example, methods and materials for assessing a mammal's gut microbial diversity to identify the mammal as having arthritis (e.g., rheumatoid arthritis) are provided. This document also provides methods and materials involved in treating arthritis.

A method of reducing growth of pathogenic bacteria in a gastrointestinal tract of an animal by providing to the animal a composition having 110.sup.13 cfu of Lactobacillus probiotic microorganisms per kilogram of feed. When 110.sup.4 viable cells of the Lactobacillus probiotic are added to 110.sup.4 viable cells of Escherichia coli in a solution of MRS broth in a test tube and incubated in a water bath at 37 C. for six hours, the growth of Escherichia coli is reduced compared to a preparation of 110.sup.4 viable cells of Escherichia coli mixed in a solution of MRS broth in a test tube and incubated in a water bath at 37 C. for six hours without the addition of Lactobacillus probiotic.

A method of reducing growth of pathogenic bacteria in a gastrointestinal tract of an animal by providing to the animal a composition having 110.sup.13 cfu of Lactobacillus probiotic microorganisms per kilogram of feed. When 110.sup.4 viable cells of the Lactobacillus probiotic are added to 110.sup.4 viable cells of Escherichia coli in a solution of MRS broth in a test tube and incubated in a water bath at 37 C. for six hours, the growth of Escherichia coli is reduced compared to a preparation of 110.sup.4 viable cells of Escherichia coli mixed in a solution of MRS broth in a test tube and incubated in a water bath at 37 C. for six hours without the addition of Lactobacillus probiotic.

The present disclosure relates to methods and compositions suitable for changing metabolite levels in a subject in need thereof. In particular, this application provides methods and compositions for changing metabolite levels in a subject diagnosed with Autism Spectrum Disorder (ASD). Methods of preventing or treating an ASD in a subject thereof, as well as methods of selecting a treatment plan for treating an ASD in a subject are also provided.

The present disclosure provides anti-Salmonella antibodies or antibody fragments such as camelid single domain antibodies (VHHs), along with associated nucleic acids, host cells and phages. Methods of reducing the presence of Salmonella in an animal or an animal environment, methods and formulations for treating Salmonella infection, and methods of detecting Salmonella are also described.